Details of the Drug Combination

General Information of Drug Combination (ID: DCBFZP3)

Drug Combination Name
Pregabalin Diphenhydramine
Indication
Disease Entry Status REF
Lumbar Spinal Stenosis Phase 1 [1]
Component Drugs Pregabalin   DMDVP3B Diphenhydramine   DMKQTBA
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pregabalin
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Approved [2]
Epilepsy 8A60-8A68 Approved [3]
Pain MG30-MG3Z Approved [3]
Postherpetic neuralgia 1E91.5 Approved [3]
Vulvodynia N.A. Approved [3]
Chronic pain MG30 Investigative [3]
Neuralgia N.A. Investigative [3]
Pregabalin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) TTFK1JQ CA2D1_HUMAN Modulator [6]
------------------------------------------------------------------------------------
Pregabalin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
L-type amino acid transporter 1 (SLC7A5) DT48T0N LAT1_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Indication(s) of Diphenhydramine
Disease Entry ICD 11 Status REF
Hyperemesis gravidarum N.A. Approved [4]
Insomnia 7A00-7A0Z Approved [4]
Meniere disease AB31.0 Approved [5]
Nausea MD90 Approved [4]
Seasonal allergic rhinitis CA08.01 Approved [4]
Vasomotor/allergic rhinitis CA08 Approved [4]
Vomiting MD90 Approved [4]
Diphenhydramine Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Histamine N-methyltransferase (HNMT) TT2B6EV HNMT_HUMAN Inhibitor [8]
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [9]
------------------------------------------------------------------------------------
Diphenhydramine Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [12]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Diphenhydramine Interacts with 10 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Decreases Activity [13]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Decreases Expression [14]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [14]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Increases Expression [14]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [14]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Decreases Expression [14]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [14]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Activity [15]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Decreases Expression [14]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DOT(s)

References

1 ClinicalTrials.gov (NCT00638443) Lumbar Stenosis Outcomes Research (LUSTOR)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5484).
3 Pregabalin FDA Label
4 Diphenhydramine FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76.
7 Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Pharm Res. 2018 Oct 29;35(12):246.
8 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
10 Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
11 Pharmacogenomics in psychiatry: implications for practice. Recent Pat Biotechnol. 2014;8(2):152-9.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
14 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
15 First-generation antihistamines diphenhydramine and chlorpheniramine reverse cytokine-afforded eosinophil survival by enhancing apoptosis. Allergy Asthma Proc. 2007 Jan-Feb;28(1):79-86. doi: 10.2500/aap.2007.28.2961.